The Odyssey

March 1, 2021

John J. Miller, MD

Video

What dementia treatment makes an interesting appearance in classical literature?

John J. Miller, MD, talks about approved treatments for early, mild-to-moderate dementia, one of which makes an appearance in "The Odyssey."

Dr Miller is medical director, Brain Health, Exeter, NH; editor in chief, Psychiatric TimesTM; staff psychiatrist, Seacoast Mental Health Center, Exeter, NH; consulting psychiatrist, Exeter Hospital, Exeter, NH; consulting psychiatrist, Insight Meditation Society, Barre, MA.

Related Videos

Video 6 - "Future Perspectives on Schizophrenia Care"

Video 2 - "Pathophysiology of Narcolepsy and the Role of Orexins"

Video 1 - "Definition of Narcolepsy and Unmet Needs"

Video 4 - "Physician Awareness of Cognitive Dysfunction in Schizophrenia"

Video 3 - "Insights on the Pathophysiology of Schizophrenia"

Video 2 - "Exploration into the Management of the Three Symptom Domains of Schizophrenia"

dementia

“What we’re striving to do is conquer the unmet needs that are still here with treating ADHD, especially from a medication standpoint.”

Related Content

Peter J. Weiden, MD, sat down with Psychiatric Times’ Editor-in-Chief at the 2024 Annual Meeting. Here’s Part 2 of their conversation.

Long-Acting Injectable vs Oral Antipsychotics: Part 2 of a Conversation With Peter J. Weiden, MD

Peter J. Weiden, MD, sat down with Psychiatric Times’ Editor-in-Chief at the 2024 Annual Meeting. Here’s Part 1 of their conversation.

Long-Acting Injectables: Part 1 of a Conversation With Peter J. Weiden, MD

The Psychiatric Times Substance Use Section Editor reflects on the theme of the 2024 Annual Meeting, plus what he is most excited about in psychiatry.

The Role of Addiction in Treatment Plans and Outcomes

Philip R. Muskin, MD, MA, DLFAPA, LFACLP, discusses contemporary psychiatry and some of the most exciting things about the 2024 Annual Meeting.

The 3 Biggest Challenges in Psychiatry Today

Rikinkumar Patel, MD, MPH, shares some recent research findings with Psychiatric Times at the 2024 Annual Meeting.

The Inpatient Setting vs the Time of the Year in Hospitalized Child and Adolescent Patients

How does artificial intelligence have the potential to shape the future of psychiatry?

Making Sense of Chatbots

Related Content

Peter J. Weiden, MD, sat down with Psychiatric Times’ Editor-in-Chief at the 2024 Annual Meeting. Here’s Part 2 of their conversation.

Long-Acting Injectable vs Oral Antipsychotics: Part 2 of a Conversation With Peter J. Weiden, MD

Peter J. Weiden, MD, sat down with Psychiatric Times’ Editor-in-Chief at the 2024 Annual Meeting. Here’s Part 1 of their conversation.

Long-Acting Injectables: Part 1 of a Conversation With Peter J. Weiden, MD

The Psychiatric Times Substance Use Section Editor reflects on the theme of the 2024 Annual Meeting, plus what he is most excited about in psychiatry.

The Role of Addiction in Treatment Plans and Outcomes

Philip R. Muskin, MD, MA, DLFAPA, LFACLP, discusses contemporary psychiatry and some of the most exciting things about the 2024 Annual Meeting.

The 3 Biggest Challenges in Psychiatry Today

Rikinkumar Patel, MD, MPH, shares some recent research findings with Psychiatric Times at the 2024 Annual Meeting.

The Inpatient Setting vs the Time of the Year in Hospitalized Child and Adolescent Patients

How does artificial intelligence have the potential to shape the future of psychiatry?

Making Sense of Chatbots

Terms and Conditions

Do Not Sell My Personal Information

Contact Info

2 Commerce Drive
Cranbury, NJ 08512

© 2024 MJH Life Sciences

All rights reserved.